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The effects of polarized-light therapy (PLT) on high-cholesterol diet (HCD)-induced hypercholesterolemia
and atherosclerosis were investigated in comparison with that of lovastatin in rabbits. Hypercholesterolemia
was induced by feeding male New Zealand white rabbits with 1% cholesterol in diet for 2 weeks and
maintained with 0.5% cholesterol for 6 weeks, followed by normal diet for 2 weeks for recovery.
Lovastatin (0.002% in diet) or daily 5-min or 20-min PLT on the outside surface of ears was started 2
weeks after induction of hypercholesterolemia. Hypercholesterolemic rabbits exhibited great increases in
serum cholesterol and low-density lipoproteins (LDL) levels, and finally severe atheromatous plaques
formation covering 57.5% of the arterial walls. Lovastatin markedly reduced both the cholesterol and LDL,
but the reducing effect (47.5%) on atheroma formation was relatively low. By comparison, 5-min PLT
preferentially decreased LDL, rather than cholesterol, and thereby potentially reduced the atheroma area
to 42.2%. Notably, 20-min PLT was superior to lovastatin in reducing both the cholesterol and LDL levels
as well as the atheromatous plaque formation (26.4%). In contrast to the increases in blood alanine
transaminase and aspartate transaminase following lovastatin treatment, PLT did not cause hepatotoxicity.
In addition, PLT decreased platelets and hematocrit level. The results indicate that PLT attenuates
atherosclerosis not only by lowering blood cholesterol and LDL levels, but also by improving blood flow
without adverse effects. Therefore, it is suggested that PLT could be a safe alternative therapy for the
improvement of hypercholesterolemia and atherosclerosis.
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In Korea, the patterns of disease have changed
dramatically in parallel with rapid economic development,
accompanied by Westernization of lifestyles [1]. Recently,
according to the change in the pattern of food
consumption, the incidence rate of metabolic syndromes
such as obesity, stroke, atherosclerosis, hypertension,
diabetes and cancer are considerably increasing [2,3].
Especially, hyperlipidemia is becoming the main cause
of health problems [4].
The major risk factors of cardiovascular diseases are
increasing levels of total cholesterol, triglycerides (TG)
and low-density lipoproteins (LDL) accompanying
decrease in high-density lipoproteins (HDL) [5,6]. It has
been reported that increased consumption of cholesterol
and triglycerides is closely associated with hyper-
cholesterolemia, leading to atherosclerosis [7,8].
Hypercholesterolemia is an important risk factor of
atherosclerosis [9,10]. LDL, major transporter of blood
cholesterol, is oxidized in the endothelium of arterial
walls and induces infiltration of circling monocytes
following endothelial cell injuries. Oxidized LDL
(OxLDL) stimulates vascular endothelial cells to produce
monocyte-colony stimulating factor (M-CSF) and
induces differentiation of infiltrated monocytes to
macrophages [11]. Then, LDL binds to several scavenger
receptors expressed on macrophages instead of LDL
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receptors, one of the superficial receptor of macrophages,
disrupting feedback controlling mechanism of intracellular
cholesterol level. Macrophages that contain highly
enriched cholesterol become foam cells and form fatty
streak namely atheromatous plaques, initial lesion of
atherosclerosis [12].
Several drugs that are clinically used to treat for
hyperlipidemia are classified as 3-hydroxy-3-methylglutanyl-
coenzyme A (HMG-CoA) reductase inhibitor (statins),
bile acid sequestrant (resin), nicotinic acid, fibrate and
probucol [13,14]. Among them, statins inhibit HMG-
CoA reductase, rate-limiting step enzyme in cholesterol
biosynthesis, thereby reduce intracellular cholesterol
level. Statins also increase the activity of LDL receptors
on cell membrane, accelerating the metabolism of very
low-density lipoproteins (VLDL) remnant and LDL
[15]. Even though drugs with such mechanism have an
advantage to lower blood cholesterol level remarkably,
but they exert serious adverse effects like hepatomegaly
and renal hypertrophy [16,17]. Thus, researches on the
development of natural resources with a novel mechanism
without side effects are required.
It is well known that light with specific wavelength
exerts influence on organisms, which has been reconsidered
in terms of modern medicine [18]. Although sunlight
had been believed to have beneficial effects on health in
Egypt in B.C., it has been for the treatment of diseases
in 1990s [19]. Especially, in 1960s, some studies showed
that sunlight has a significant influence on feelings of
daily life as well as physical and mental health [20].
Recently, it has been demonstrated that ultraviolet rays,
far-infrared radiation, laser and visible lights including
sunlight were applicable for disinfection and health
improvement. For example, in late 1980s, Low-Level-
Light Therapy (LLLT) using narrow-band (632.8 nm)
light has been developed for the relief of pain and
inflammation as well as for immune-boosting and
wound-healing effects [21-26]. Moreover, various light
therapies are being studied from a medical perspective
[27].
Notably, several studies showed that Polarized-Light
Therapy (PLT), using strained broad-band (400-760 nm)
visible light through a polarizing lens, exhibited greater
pain-relieving effects than LLLT with narrow-band
wavelength [21-23,25,26]. Recently, it was confirmed
that PLT improved blood circulation and blood pressure
of hypertensive patients by reducing fibrinogen, platelets
and blood viscosity, preventing aggregation of platelets,
and delaying blood coagulation time (unpublished results).
PLT displayed additional beneficial effects: i.e., decreasing
blood cholesterol and triglycerides, improving immune
function, relieving pain and inflammation, and facilitating
wound healing in human studies (unpublished results).
Therefore, such results led us to investigate the
improving effects of PLT on high-cholesterol diet
(HCD)-induced hypercholesterolemia and atherosclerosis
in comparison with lovastatin, a clinically available
cholesterol-controlling statin, in rabbits.
Materials and Methods
Materials
The PLT equipment is consisted of a 60 W tungsten
lamp and a lens coated with polarized film in a stainless
tube with 6-cm internal diameter. The polarized film
(Nucell Biomedics, Cheongju, Korea) was designed to
block ultraviolet and infrared lights, permitting penetration
of only 400-760 nm light, which was confirmed by
prism analysis at Photonics Polymer Laboratory
(Gwangju, Korea). The distance between light source and
polarized-light lens was set at 10 cm to adjust the light
intensity and energy density exposed to the skin to be
50 mW/cm
2 and 60 J/cm
2, respectively.
An anti-cholesterol reference drug Meverstin
® containing
lovastatin as an active ingredient was purchased from
Choongwae Pharma Co. (Seoul, Korea). Cholesterol
used to induce hypercholesterolemia and atherosclerosis
was procured from Sigma-Aldrich (C75209; St. Louis,
MO, USA).
Animals
Six-month-old male New Zealand white (NZW)
rabbits (n=8/group) weighing 1.7-2.0 kg were from
Daehan-Biolink (Eumseong, Korea), and subjected to
the experiment after 1-week acclimation to the laboratory
environment. The animals were housed in each cage
with free access to feed and water under constant
environmental conditions (22±2
oC; 40-70% relative
humidity; 12-hour light-dark cycle; 150-300 lux
brightness). Animals were checked for abnormal sign
every day and weighed once a week. All the animal
experiments were conducted according to the Standard
Operation Procedures, and approved by the Institutional
Animal Care and Use Committee of Chungbuk National
University, Korea.Anti-cholesterolemic and anti-atherosclerotic effects of polarized-light therapy 41
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Induction hypercholesterolemia and treatment
Acute dietary hypercholesterolemia was induced by
feeding animals with a powdered high-cholesterol diet
(HCD) containing 1% cholesterol for 2 weeks, followed
by 0.5% cholesterol for additional 6 weeks during
maintenance period and normal diet without cholesterol
for recovery period of 2 weeks.
After 2-week induction of hypercholesterolemia, the
animals were grouped (n=8/group) according to their
blood cholesterol levels to adjust similar mean values.
To assess therapeutic efficacy of PLT against hyper-
cholesterolemia and atherosclerosis, the rabbits were
exposed to PLT light for 5 or 20 min on their outside
surface of ear with 10 cm distance from lens every day
(10:00-12:00) for 8 weeks. Separately, 0.002% lovastatin
was supplemented in diet for the 8-week treatment
period.
Hematology and blood biochemistry
After 16-hour fasting at the ends of 2-week cholesterolemia
induction and 10-week total experimental period (2-
week induction, 6-week maintenance and 2-week
recovery), blood sample was collected from auricular
artery, and hematocrit, red blood cells (RBC),
hemoglobin, mean corpuscular volume (MCV), mean
corpuscular hemoglobin (MCH), mean corpuscular
hemoglobin concentration (MCHC), white blood cells
(WBC), differential counts (neutrophils, eosinophils,
basophils, lymphocytes and monocytes) and platelets
were measured by a hematology analyzer (Hemavet 850;
CDC Technologies Inc., Dayton, USA).
Lipid profiles including total cholesterol, LDL, HDL,
triglycerides, fibrin-degradation products (FDP) and D-
dimer were measured in serum obtained from centrifuged
(3,000 rpm×20 min) blood. Parameters of hepatic
function such as alanine transaminase (ALT), aspartate
transaminase (AST), alkaline phosphatase (ALP) and
total bilirubin were analyzed by blood chemistry
analyzer (Hitachi-747; Hitachi Korea, Seoul, Korea).
Evaluation of atherosclerosis
The aortic arch (14 cm) was dissected from the aortic
valve of the heart and washed with saline. The sample
was dissected in 10 cm long from the orifice of carotid
artery, and opened longitudinally. After removing fats
and tissues adhering to the adventitia, the aorta was
dehydrated with 100% propylene glycol for 10 min, and
stained with 0.7% Sudan IV (in propylene glycol) for 10
min. Then, it was hydrated with 85% propylene glycol
for 5 min, washed with distilled water, and photographed
and analyzed with Digital Image Analyzer (Image Inside;
Focus, Seoul, Korea) for red atheromatous plaques. The
extent of lipid accumulation (atherosclerosis index; AI,
%) was calculated as the percent Sudan-positive area to
the total area of the aortic wall.
Statistical analysis
The results are presented as means±standard deviation.
The significance of differences of all results was analyzed
by one-way analysis of variance followed by the
Dunnett’s multiple-range test correction. Statistical
significance was set a priority at P<0.05.
Results
Change in body weights
In comparison with normal animals, the body weight
gain of HCD-fed animals slightly increased (Figure 1).
Daily PLT for 5 or 20 min did not affected the body
weight gain of HCD-fed rabbits, while treatment with
lovastatin (0.002% in diet) slightly reduced the body
weight gain, decreasing the final body weight below that
of normal animals. Lovastatin also caused rough skin
and hair of the animals, suggestive of a possibility of
adverse effects.
Figure 1. Change in body weight of high-cholesterol diet
(HCD)-fed rabbits (n=8) treated with lovastatin or polarized-light
therapy (PLT). Treatments were started 2 weeks following
induction of hyperchoesterolemia. ○, normal; ●, HCD; ▼,
HCD+0.002% lovastatin; ■, HCD+5 min PLT; ◆, HCD+20 min
PLT.42 Dongsun Park et al.
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Hematology
Two-week feeding of 1% HCD caused hematological
changes: increases in WBC (40-60%) and lymphocytes
(38-92%) and decreases in basophils (44-78%) and
platelets (22-30%), while hematocrit, RBC and RBC
indices were not changed (Table 1).
Meanwhile, after 8-week feeding of HCD followed by
2-week recovery period, the number of WBC was
maintained high, while basophils remained low. Notably,
platelets increased after cease of HCD feeding. However,
5-min PLT attenuated the platelets increase, and 20-min
PLT substantially inhibited the increases in hematocrit,
WBC and platelets. Whereas, lovastatin did not exhibit
any effects, except increasing lymphocytes and monocytes.
Hence it is considered that PLT improves blood flow
more effectively by alleviating hemoconcentration,
inflammatory WBC and thrombosis-inducing platelets.
Blood biochemistry
After 2-week feeding of 1% cholesterol, total cholesterol
dramatically elevated to 1,720.0-1,736.7 mg/dL from
51.8 mg/dL of normal level (Table 2). Accordingly, LDL
also increased to 651.1-684.2 mg/dL from 24.5 mg/dL in
normal animals, although there was a slightly increase in
HDL levels to 29.0-32.4 mg/dL from 18.0 mg/dL. These
changes of lipoproteins induced increase in FDP (3.8-7.1
µg/dL), a metabolite of fibrin, although another fibrin
metabolite D-dimer and triglycerides were not
remarkably affected. ALP, an indicator of cholestasis
slightly increased, without alterations in ALT and AST,
parameters of hepatocytic damage.
In 10 weeks after 8-week feeding of HCD and 2-week
recovery, blood cholesterol, LDL and FDP were recovered
to 1,415.0mg/dL, 475.5mg/dL and 1.6µg/dL, respectively.
Lovastatin significantly reduced both the cholesterol and
Table 1. Hematology of rabbits (n=8) fed a high-cholesterol (HCD) for 2 weeks followed by lovastatin treatment or polarized-light
therapy (PLT) for 8 weeks (6-week maintenance and 2-week recovery periods)








6/µL) 5.6±0.5 6.1±0.3 5.9±0.5 5.6±0.7 5.9±0.5
Hemoglobin (g/dL) 11.7±0.8 12.5±0.6 12.6 ±1.0 11.8±1.2 12.2±0.8
Hematocrit (%) 37.4±2.3 39.7±1.9 39.8±3.2 38.1±3.7 38.5±1.5
MCV (fL) 67.5±2.9 65.6±3.2 67.6±1.5 68.4±3.2 65.2±3.1
MCH (pg) 21.1±0.5 20.6±0.4 21.3±0.2 21.2±1.0 20.6±0.5
MCHC (g/dL) 31.4±0.7 31.5±1.4 31.6±0.6 31.1±0.6 31.7±1.1
WBC (×10
3/µL) 5.2±1.2 7.3±1.4 8.2±1.6 8.5±2.7 8.5±1.7
Neutrophils (%) 88.5±1.9 85.4±6.0 87.9±4.0 86.0±1.9 87.4±2.8
Eosinophils (%) 1.1±0.3 0.9±0.4 1.2±0.4 1.0±0.3 0.7±0.3
Basophils (%) 0.9±0.4 0.3±0.4 0.5±0.3 0.2±0.2 0.4±0.4
Lymphocytes (%) 5.3±1.7 10.2±5.6 7.3±3.3 8.8±2.0 7.8±2.7
Monocytes (%) 4.1±1.3 3.2±1.1 3.3±0.8 4.0±0.5 3.8±1.4
Platelets (×10
3/µL) 372.5±168.2 288.8±51.6 261.5±51.9 280.0±66.9 267.2±54.4
After treatment
RBC (×10
6/µL) 5.0±1.1 5.2±0.8 4.8±0.5 4.8±0.9 4.5±0.4
Hemoglobin (g/dL) 11.2±2.1 11.8±1.5 11.1±0.9 10.9±1.6 10.5±0.9
Hematocrit (%) 36.1±6.1 37.9±3.8 35.7±3.5 36.2±5.4 34.2±2.2
MCV (fL) 73.5±7.4 73.2±4.9 74.3±3.3 75.4±3.8 77.0±2.9
MCH (pg) 22.8±2.0 22.6±1.3 23.1±0.8 22.6±1.1 23.6±0.5
MCHC (g/dL) 31.0±0.6 30.9±1.1 31.2±0.8 30.0±0.4 30.6±1.0
WBC (×10
3/µL) 6.5±2.4 8.1±1.7 8.0±3.2 8.0±1.5 6.8±1.1*
Neutrophils (%) 88.5±2.8 87.1±3.0 83.7±11.4 88.3±2.8 86.3±6.1
Eosinophils (%) 1.0±0.4 1.2±0.2 1.0±0.5 1.1±0.5 0.8±0.4
Basophils (%) 1.5±1.1 0.5±0.4 0.5±0.2 0.6±0.7 0.5±0.3
Lymphocytes (%) 5.3±2.4 6.6±2.6 8.5±9.2 5.0±2.7 7.7±3.8
Monocytes (%) 4.2±1.6 4.8±0.8 6.6±2.9 5.2±1.8 4.7±2.3
Platelets (×10
3/µL) 322.0±125.0 410.3±79.6 399.7±100.6 350.5±80.6 329.5±31.3*
*Significantly different from HCD alone, P<0.05.Anti-cholesterolemic and anti-atherosclerotic effects of polarized-light therapy 43
Lab Anim Res | March, 2012 | Vol. 28, No. 1
LDL levels to 855.0 and 280.1 mg/dL, respectively. In
comparison, 5-min PLT lowered LDL level more
preferably than cholesterol. Interestingly, 20-min PLT
markedly decreased both the cholesterol and LDL levels
comparable with lovastatin. More importantly, lovastatin
significantly increased the blood ALT and AST values,
indicative of hepatotoxicity, in contrast to the normal
levels in PLT animals.
Time-course of blood cholesterol and LDL
During 6-week feeding of 0.5% cholesterol diet, the
blood cholesterol level maintained high (Figure 2),
although LDL recovered gradually (Figure 3). Lovastatin
significantly decreased the cholesterol level from 2-
week treatment to reach 2-third level after 6-week
feeding. Five-min PLT also reduced the blood cholesterol
level after 4-week treatment, although the statistical
significance was not achieved. Notably, 20-min PLT
markedly lowered the cholesterol level even in higher
degree than lovastatin. Similar effects of lavastatin and
20-min PLT were obtained on blood LDL level.
Importantly, 5-min PLT also exerted a remarkable
efficacy in LDL reduction.
Atherosclerotic index
Feeding HCD with 1% cholesterol for 2 weeks, 0.5%
cholesterol for 6 weeks and recovery for 2 weeks caused
Table 2. Blood biochemistry of rabbits (n=8) fed a high-cholesterol (HCD) for 2 weeks followed by lovastatin treatment or polarized-
light therapy (PLT) for 8 weeks (6-week maintenance and 2-week recovery periods)







Cholesterol (mg/dL) 51.8±12.9 1,722.0±156.20, 1,726.7±231.10, 1,720.0±233.80, 1,736.7±165.00,
LDL (mg/dL) 24.5±9.90 651.1±45.20 651.7±44.00 663.3±67.40 684.2±43.20
HDL (mg/dL) 18.0±5.60 32.4±4.20 29.0±9.40 29.5±5.40 32.2±5.50
Triglycerides (mg/dL) 40.8±7.20 41.8±22.3 40.8±23.1 41.8±20.1 41.7±10.7
FDP (µg/dL) 0.0±0.0 7.1±5.9 3.8±2.3 4.2±3.0 4.2±2.9
D-dimer (µg/dL) 0.6±0.8 0.1±0.1 0.5±0.3 0.7±0.4 0.7±0.5
ALT (U/L) 45.0±16.5 48.4±15.0 54.5±21.8 53.5±11.1 48.3±11.8
AST (U/L) 29.7±19.7 27.4±3.40 39.8±25.8 30.5±5.40 27.7±6.10
ALP (U/L) 354.2±127.2 447.8±129.4 457.2±86.10 386.5±124.9 356.8±81.10
Bilirubin (mg/dL) 0.2±0.2 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0
After treatment
Cholesterol (mg/dL) 57.5±15.4 1,415.0±154.30, 0855.0±143.8* 1,136.0±234.400 938.1±128.3*
LDL (mg/dL) 21.8±4.40 475.5±55.40 280.1±26.5* 386.1±42.0* 295.1±28.7*
HDL (mg/dL) 28.0±11.4 29.7±8.80 27.7±10.7 31.0±5.90 34.8±5.70
Triglycerides (mg/dL) 46.7±13.0 56.8±35.6 46.8±26.7 68.7±56.3 72.8±34.3
FDP (µg/dL) 1.6±1.7 1.0±0.8 1.1±0.8 2.0±1.6 1.3±0.6
D-dimer (µg/dL) 1.0±1.4 0.5±0.5 2.0±4.1 0.5±0.1 0.6±0.7
ALT (U/L) 54.0±20.6 34.7±11.1 *82.5±15.9* 30.3±9.20 32.5±11.4
AST (U/L) 34.5±12.6 27.0±7.40* 63.7±17.7* 26.8±5.90 27.0±5.70
ALP (U/L) 231.2±27.80 248.7±30.20 237.2±42.30 231.5±46.90 188.0±26.4*
Bilirubin (mg/dL) 0.0±0.1 0.0±0.1 0.0±0.1 0.0±0.1 0.1±0.1
*Significantly different from HCD alone, P<0.05.
Figure 2. Time-course of blood cholesterol level in high-
cholesterol diet (HCD)-fed rabbits (n=8) treated with lovastatin
or polarized-light therapy (PLT). Treatments were started 2
weeks following induction of hypercholesterolemia. ○, normal;
●, HCD; ▼, HCD+0.002% lovastatin; ■, HCD+5 min PLT; ◆,
HCD+20 min PLT. *Significantly different from HCD alone,
P<0.05.44 Dongsun Park et al.
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extensive atheromatous plaques covering 57.5% of the
aortic arch and abdominal artery (Figure 4 and Table 3).
The degree of atheromatous plaques formation was
attenuated by treatment with lovastatin to 47.5%.
However, the anti-atherosclerotic activity of PLT was
superior to lovastatin: 5-min and 20-min PLT decreased
the plaque area to 42.2% and 26.4%, respectively.
Discussion
To investigate the PLT’s effects on blood lipid profiles
and change in vessel walls, HCD was fed to rabbits to
induce hypercholesterolemia and ensuing atherosclerosis.
Rabbits has been used to study atherosclerosis because
their enzyme activity of cholesterol ester transfer proteins
(CETP), a causative factor of arteriosclerosis in human,
is three times higher than human, so that hyper-
cholesterolemia can be induced in a short period and
lesions such as foam cells and fatty streak be easily
induced [28].
Lovastatin is a metabolic derivate of Aspergillus terreus
and preferentially prescribed for hypercholesterolemia
and cardiovascular diseases. Lovastatin, as HMG-CoA
reductase inhibitor, suppress cholesterol synthesis and
improves bile duct secretion [29-31]. Accordingly,
lovastatin remarkably reduced cholesterol and LDL after
2-week feeding in the present study. Compare to
lovastatin, 5-min PLT did not show any effects on
cholesterol and LDL within 2 weeks. However, 5-min
PLT remarkably reduced the LDL level, a key factor of
atheroma formation, from 4-week therapy. Moreover,
20-min PLT markedly lowered both the cholesterol and
LDL levels with higher efficacy than lovastatin.
It is of interest to note that 5-min PLT was more
effective in the suppression of atheromatous lesion
formation than lovastatin, in spite of the lower activity
on cholesterol and LDL. Accordingly, 20-min PLT was
much superior to lovastatin in the prevention of
atherosclerosis, in which blood lipid levels were lowered
Figure 4. Representative findings of the aorta of high-
cholesterol diet (HCD)-fed rabbits (n=8) treated with lovastatin
(0.002%) or 5 min or 20 min polarized-light therapy (PLT). Note
extensive atheromatous plaques induced by HCD and marked
attenuation by 20 min PLT, in comparison with intact features in
rabbits fed normal diet.
Figure 3. Time-course of blood low-density lipoproteins (LDL)
level of high-cholesterol diet (HCD)-fed rabbits (n=8) treated
with lovastatin or polarized-light therapy (PLT). Treatments were
started 2 weeks following induction of hypercholesterolemia. ○,
normal; ●, HCD; ▼, HCD+0.002% lovastatin; ■, HCD+5 min
PLT; ◆, HCD+20 min PLT. *Significantly different from HCD
alone, P<0.05.
Table 3. Atheromatous plaques formed in the aorta of high-cholesterol diet (HCD)-fed rabbits (n=8) treated with lovastatin or
polarized-light therapy (PLT)
Treatment Total area (cm
2) Atheroma area (cm
2) Relative area (%)
Normal 4.875±0.396 0.000±0.000 0.0±0.0
HCD 4.796±0.471 2.758±0.992 57.5±10.6
+Lovastatin (0.002%) 5.145±0.575 2.444±1.064 47.5±8.40
+PLT (5 min) 5.132±0.222 2.159±0.624 42.2±7.5*
+PLT (20 min) 4.822±0.492 1.218±0.816 26.4±8.1*
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to similar extents to lovastatin. Therefore, it is estimated
that, in addition to the lipid-lowering activity, PLT might
inhibit oxidation and accumulation in the aortic wall of
LDL, although the exact mechanisms remain to be
clarified. In addition, PLT decreased platelets and
hematocrit level related to the improvement of blood
flow. PLT also decreased WBC, while lovastatin increased
lymphocytes and monocytes. Hence it is considered that
PLT improves blood flow more effectively by alleviating
hemoconcentration, inflammatory WBC and thrombosis-
inducing platelets.
In blood biochemistry, ALT and AST significantly
increased following lovastatin treatment. The hepatotoxicity
is a critical factor limiting long-term use of high dose
lovastatin. It was reported in previous studies that statins
caused hepatic injuries with increases in ALT and AST
as well as hepatobiliary dysfunction, myocardial
degeneration, fetal malformations with skeletal defects
presumably by disrupting lipid-metabolic processes
[32,33]. PLT did not induce ALT and AST increases, and
20-min PLT rather lowered the HCD-induced increase in
ALP, a parameter of cholestasis.
In the present study, it was demonstrated that PLT
substantially attenuated atherosclerosis not only by
lowering blood cholesterol and LDL levels, but also by
improving blood flow without adverse effects such as
hepatotoxicity. Therefore, it is suggested that PLT could
be an alternative therapy for the improvement of
hypercholesterolemia and prevention of atherosclerosis.
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